Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

van Dyck, C H; Newhouse, P; Falk, W E; Mattes, J A

van Dyck, C H; Newhouse, P; Falk, W E; Mattes, J A.

Affiliation

van Dyck CH; Department of Psychiatry, Yale University School of Medicine, New Haven, Conn 06520, USA. christopher.vandyck@yale.edu

Arch Gen Psychiatry ; 57(2): 157-64, 2000 Feb.

Article in En | MEDLINE | ID: mdl-10665618

Subject(s)

Alzheimer Disease/drug therapy; Cholinesterase Inhibitors/therapeutic use; Physostigmine/therapeutic use; Aged; Aged, 80 and over; Alzheimer Disease/diagnosis; Alzheimer Disease/psychology; Cholinesterase Inhibitors/administration & dosage; Cognition Disorders/diagnosis; Cognition Disorders/drug therapy; Cognition Disorders/psychology; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea/chemically induced; Neuropsychological Tests; Physostigmine/administration & dosage; Physostigmine/adverse effects; Placebos; Treatment Outcome; Vomiting/chemically induced

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Physostigmine / Cholinesterase Inhibitors / Alzheimer Disease Type of study: Clinical_trials / Diagnostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Arch Gen Psychiatry Year: 2000 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links